Advanced search
Publication Cover
Acute Cardiac Care Volume 9, 2007 - Issue 3
Journal homepage
20
Views
0
CrossRef citations to date
0
Altmetric
Invited Synopses

Invited Synopses

Pages 134-174 | Published online: 10 Jul 2009

References

  • Jaffe A. S., Babuin L., Apple F. S. Biomarkers in Acute Cardiac Disease: The Present and the Future. JACC 2006; 48((1))1–11
  • Topol E. J., Nissen S. E. Our preoccupation with coronary luminology. The dissociation between clinical and angiographic findings in ischemic heart disease. Circulation 1995; 92: 2333–42
  • Martinez M. W., Babuin L., Syed I. S., Feng D. L., Miller W. L., Mathew V., Breen J. F., Jaffe A. S. Myocardial infarction with normal coronary arteries: a role for MRI?. Clinical Chemistry 2007; 53: 995–6
  • Christiansen J. P., Edwards C., Sinclair T., Armstrong G., Scott A., Patel H., et al. Detection of myocardial scar by contrast‐enhanced cardiac magnetic resonance imaging in patients with troponin‐positive chest pain and minimal angiographic coronary artery disease. Am J Cardiol 2006; 97: 768–771
  • Mahrholdt H., Goedecke C., Wagner A., Meinhardt G., Athanasiadis A., Vogelsberg H., et al. Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation 2004; 109: 1250–1258
  • Bybee K. A., Prasad A., Barsness G. W., Lerman A., Jaffe A. S., Murphy J. G., Wright R. S., Rihal C. S. Clinical Characteristics and Thrombolysis in Myocardial Infarction Frame Counts in Women With Transient Left Ventricular Apical Ballooning Syndrome. Am J Cardiol 2004; 94: 343–346
  • Guest T. M., Ramanathan A. V., Schechtman K. B., Ladenson J. H., Jaffe A. S. Myocardial injury in critically ill medical patients: A surprisingly frequent complication. JAMA 1995; 273: 1945–1949
  • Landesberg G., Shatz V., Akopnik I., Wolf Y. G., Mayer M., Berlatzky Y., Weissman C., Mosseri M. Association of cardiac troponin, CK‐MB, and postoperative myocardial ischemia with long‐term survival after major vascular surgery. Journal of the American College of Cardiology 2003; 42: 1547–54
  • Bursi F., Babuin L., Barbieri A., Politi L., Zennaro M., Grimaldi T., Rumolo A., Gargiulo M., Stella A., Grazia Modena M., Jaffe A. S. Vascular surgery patients: perioperative and long‐term risk according to the ACC/AHA guidelines, the additive role of post‐operative troponin elevation. European Heart Journal 2005; 26: 2448–2456

References

  • Kobal S. L., Atar S., Siegel R. J. Hand‐carried ultrasound improves the bedside cardiovascular examination. Chest 2004; 126: 693–701
  • Rugolotto M., Hu B. S., Liang D. H., Schnittger I. Rapid assessment of cardiac anatomy and function with a new hand‐carried ultrasound device (OptiGo): a comparison with standard echocardiography. Eur J Echocardiogr 2001; 2: 262–9
  • Weston P., Alexander J. H., Patel M. R., Maynard C., Crawford L., Wagner G. S. Hand‐held echocardiographic examination of patients with symptoms of acute coronary syndromes in the emergency department: the 30‐day outcome associated with normal left ventricular wall motion. Am Heart J 2004; 148: 1096–101
  • Atar S., Feldman A., Darawshe A., Siegel R. J., Rosenfeld T. Utility and diagnostic accuracy of hand‐carried ultrasound for emergency room evaluation of chest pain. Am J Cardiol 2004; 94: 408–9
  • Bruce C. J., Montgomery S. C., Bailey K. R., Tajik J., Seward J. B. Utility of hand‐carried ultrasound devices used by cardiologists with and without significant echocardiographic experience in the cardiology inpatient and outpatient settings. Am J Cardiol 2002; 90: 1273–5
  • DeCara J. M., Lang R. M., Koch R., Bala R., Penzotti J., Spencer K. T. The use of small personal ultrasound devices by internists without formal training in echocardiography. Eur J Echocardiogr 2003; 4: 141–7

References

  • Pope J. H., Aufderheide T. P., Ruthazer R., et al. Missed diagnoses of acute cardiac ischemia in the emergency department. N Engl J Med 2000; 342: 1163–1170
  • Karcz A., Korn R., Burke M. C., et al. Malpractice claims against emergency physicians in Massachusetts: 1975–1993. Am J Emerg Med 1996; 14: 341–345
  • Raff G. L., Gallagher M. J., O'Neill W. W., et al. Quantitative and qualitative accuracy of non‐invasive coronary angiography using 64‐slice helical computed tomography. J Am Coll Cardiol 2005; 46: 552–557
  • Mollet N. R., Cademartiri F., van Mieghem C. A. G., et al. High‐resolution spiral computed tomography coronary angiography in patients referred for diagnostic conventional coronary angiography. Circulation 2005; 112: 2318–2323
  • Leschka S., Alkadhi H., Plass A., et al. Accuracy of MSCT coronary angiography with 64‐slice technology: first experience. Eur Heart J 2005; 26: 1482–1487
  • Gallagher M. J., Ross M. A., Raff G. L., Goldstein J. A., O'Neill W. W., et al. The diagnostic accuracy of 64‐slice computed tomography coronary angiography compared with stress nuclear imaging in emergency department low‐risk chest pain patients. Ann Emerg Med 2007; 49: 125–36

References

  • DeWood M. A., Spores J., Notske R., et al. Prevalence of total coronary occlusion during the early hours of transmural infarction. N Engl J Med 1980; 303: 897–902
  • Khaja F., Walton J. A., Jr., Brymer J. F., et al. Intracoronary fibrinolytic therapy in acute myocardial infarction: report of a prospective randomized trial. N Engl J Med 1983; 308: 1305–1311
  • Kennedy J. W., Ritchie J. L., Davis K. B., et al. Western Washington randomized trial of intracoronary streptokinase in the treatment of acute myocardial infarction. N Engl J Med 1983; 309: 1477–1482
  • Reimer K. A., Jennings R. B. The “wave‐front phenomenon” of myocardial ischemic cell death, 2. Transmural progression of necrosis within the frame‐work of ischemic bed size (myocardium at risk) and collateral flow. Lab Invest 1979; 40: 633–644
  • Schroder R., Biamino G., Leitner E. R., et al. Intravenous short‐term infusion of streptokinase in acute myocardial infarction. Circulation 1983; 67: 536–548
  • Ganz W., Geft I. L., Shah P. K., et al. Intravenous streptokinase in evolving acute myocardial infarction. Am J Cardiol 1984; 53: 1209–1216
  • Appelbaum D., Weiss A. T., Koren D., et al. Feasibility of pre‐hospital fibrinolytic therapy of acute myocardial infarction by emergency medical services. J Am Emerg Med 1986; 4((3))207–210
  • Koren G., Weiss A. T., Hasin Y., et al. Prevention of myocardial damage by very early treatment with intravenous streptokinase. N Engl J Med 1985; 313: 1384–1386
  • Weiss A. T., Fine D. G., Appelbaum D., et al. Pre‐hospital coronary thrombolysis: a new strategy in acute myocardial infarction. Chest 1987; 92: 124–128
  • Weiss A. T., Leitersdorf I., Gotsman M. S., et al. Prevention of congestive heart failure by early, pre‐hospital thrombolysis in acute myocardial infarction: a long‐term follow‐up study. Int J Cardiol 1998; 65: S43–S48
  • G.I.S.S.I. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 1: 397–401
  • The European Myocardial Infarction Project (EMIP). Pre‐hospital thrombolytic therapy in patients with suspected acute myocardial infarction. N Engl J Med 1993; 329: 383–389
  • GREAT Group. Feasibility, safety and efficacy of domiciliary thrombolysis by general practitioners: Grampian region early anistreplase trial. Br Med J 1992; 305: 548–553
  • Weaver W. D., Eisenberg M. E., Martin J. S., et al. Myocardial Infarction, Triage and Intervention Project‐Phase‐1:Patient characteristics and feasibility of pre‐hospital initiation of thrombolytic therapy. J Am Coll Cardiol 1990; 15: 925–931
  • Weaver W. D., Cerqueira M., Hallstrom A. P., et al. Prehospital‐initiated vs hospital‐initiated thrombolytic therapy. The Myocardial Infarction Triage and Intervention Trial. JAMA 1993; 270: 1211–1216
  • Widimsky P., Budesinsky T., Vorac D., et al. Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction: Final results of the randomized national multicentre trial PRAGUE‐2. Eur Heart J 2003; 24: 94–104
  • Keeley E. C., Boura J. A., Grines C. L., et al. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomized trials. Lancet 2003; 361: 13–20
  • Bonnefoy E., Lapostolle F., Leizerovicz A., et al. Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomized study. Lancet 2002; 360: 825–829
  • Zijlstra F., Ernst N., de Boer M. J., et al. Influence of prehospital administration of aspirin and heparin on initial patency of the infarct‐related artery in patients with ST elevation myocardial infarction. J Am Coll Cardiol 2002; 39: 1733–1737
  • Ernst N. M. S. K. J., De Boer M. J., Van de Wetering H., et al. Facilitated primary coronary angioplasty and best outcome in patients recruited in the ambulance. Eur Heart J 2003; 24: 703, abst.3617

References

  • The GISSI Investigators: Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction, Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico. Lancet 1986; 1: 397–402
  • Weaver W. D., Cerqueira M., Hallstrom A. P., Litwin P. E., Martin J. S., Kudenchuk P. J., Eisenberg M. Prehospital‐initiated vs hospital‐initiated thrombolytic therapy. The Myocardial Infarction Triage and Intervention Trial. JAMA 1993; 270: 1211–6
  • Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311–22
  • Morrison L. J., Verbeek P. R., McDonald A. C., Sawadsky B. V., Cook D. J. Mortality and prehospital thrombolysis for acute myocardial infarction: A meta‐analysis. JAMA 2000 May 24–31; 283((20))2686–92
  • Steg P. G., Bonnefoy E., Chabaud S., Lapostolle F., Dubien P. Y., Cristofini P., Leizorovicz A., Touboul P. Comparison of Angioplasty and Prehospital Thrombolysis In acute Myocardial infarction (CAPTIM) Investigators. Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial.. Circulation 2003 Dec 9; 108((23))2851–6
  • Pinto D. S., Kirtane A. J., Nallamothu B. K., Murphy S. A., Cohen D. J., Laham R. J., Cutlip D. E., Bates E. R., Frederick P. D., Miller D. P., Carrozza J. P., Jr., Antman E. M., Cannon C. P., Gibson C. M. Hospital delays in reperfusion for ST‐elevation myocardial infarction: implications when selecting a reperfusion strategy. Circulation 2006; 114: 2019–25
  • GRACIA‐2 (Groupo de Análisis de Cardiopatía Isquémica Aguda) Investigators. Primary angioplasty vs. early routine post‐fibrinolysis angioplasty for acute myocardial infarction with ST‐segment elevation: the GRACIA‐2 non‐inferiority, randomized, controlled trial.1:. Eur Heart J 2007; 28: 949–60
  • Italian Federation of Cardiology‐‐National Association of Hospital Cardiologists, Italian Society of Cardiology]: Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Lancet 1994 Feb 5; 343: 311–22
  • Cardo S., Barone A. P., Agabiti N., Greco C., Jefferson T., Guasticchi G., Gruppo di Lavoro Multidisciplinare PCAE‐Sindromi Coronariche Acute. Evidence‐based emergency pathways for patients with acute coronary syndrome]. Ital Heart J Nov 2005; 6 Suppl 6: 27S–40S
  • The DANAMI‐2 Investigators. Simple risk stratification at admission to identify patients with reduced mortality from primary angioplasty. Circulation 2005; 112: 2017–21

References

  • Eikelboom J. W., Quinlan D. J., Mehta S. R., Turpie A. G., Menown I. B., Yusuf S. Unfractionated and low‐molecular‐weight heparin as adjuncts to thrombolysis in aspirin‐treated patients with ST‐elevation acute myocardial infarction: a meta‐analysis of the randomized trials. Circulation 2005; 112((25))3855–67
  • ISIS‐3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. ISIS‐3 (Third International Study of Infarct Survival) Collaborative Group. Lancet 1992; 339((8796))753–70
  • Antman E. M., Morrow D. A., McCabe C. H., Murphy S. A., Ruda M., Sadowski Z., et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST‐elevation myocardial infarction. N Engl J Med 2006; 354((14))1477–88
  • Yusuf S., Mehta S. R., Chrolavicius S., Afzal R., Pogue J., Granger C. B., et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST‐segment elevation myocardial infarction: the OASIS‐6 randomized trial. Jama 2006; 295((13))1519–30
  • Bassand J. P., Danchin N., Filippatos G., Gitt A., Hamm C., Silber S., et al. Implementation of reperfusion therapy in acute myocardial infarction. A policy statement from the European Society of Cardiology. Eur Heart J 2005; 26((24))2733–41

References

  • Bassand J. P., Danchin N., Filippatos G., Gitt A., Hamm C., Silber S., et al. Implementation of reperfusion therapy in acute myocardial infarction. A policy statement from the European Society of Cardiology. Eur Heart J 2005; 26((24))2733–41
  • Keeley E. C., Boura J. A., Grines C. L. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003; 361((9351))13–20
  • Stenestrand U., Lindback J., Wallentin L. Long‐term outcome of primary percutaneous coronary intervention vs prehospital and in‐hospital thrombolysis for patients with ST‐elevation myocardial infarction. Jama 2006; 296((14))1749–56
  • Gershlick A. H., Stephens‐Lloyd A., Hughes S., Abrams K. R., Stevens S. E., Uren N. G., et al. Rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction. N Engl J Med 2005; 353((26))2758–68
  • Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT‐4 PCI) investigators, Primary versus tenecteplase‐facilitated percutaneous coronary intervention in patients with ST‐segment elevation acute myocardial infarction (ASSENT‐4 PCI): randomised trial. Lancet 2006; 367((9510))569–78
  • Yusuf S., Mehta S. R., Chrolavicius S., Afzal R., Pogue J., Granger C. B., et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST‐segment elevation myocardial infarction: the OASIS‐6 randomized trial. Jama 2006; 295((13))1519–30

References

  • The Task force for percutaneous coronary interventions of the European Society of Cardiology. Guidelines for percutaneous coronary interventions. European Heart Journal 2005; 26: 804–847
  • Steg P. G., Bonnefoy E., Chabaud S., Lapostolle F., Dubien P. Y., Cristofini P., Leizorovicz A., Touboul P., Comparison of Angioplasty and Prehospital Thrombolysis In acute Myocardial infarction (CAPTIM) Investigators. Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial. Circulation 2003 Dec 9; 108((23))2851–6
  • Antoniucci D., Valenti R., Migliorini A., Moschi G., Trapani M., Buonamici P., Cerisano G., Bolognese L., Santoro G. M. Relation of time to treatment and mortality in patients with acute myocardial infarction undergoing primary coronary angioplasty. Am J Cardiol 2002; 89: 1248–1252
  • De Luca G., Suryapranata H., Zijlstra F., van't Hof A. W., Hoorntje J. C., Gosselink A. T., Dambrink J. H., de Boer M. J. Symptom‐onset‐to‐balloon time and mortality in patients with acute myocardial infarction treated by primary angioplasty. J Am Coll Cardiol 2003; 42: 991–997
  • De Luca G., Suryaprenata H., Ottervanger J. P., Antman E. M. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction. Curculation 2004; 109: 1223–5
  • The task force on the management of acute myocardial infarction of the European society of cardiology. Management of acute myocardial infarction in patients presenting with ST segment elevation. European Heart Journal 2003, (24): 28–66
  • Antman E. M., et al. Management of patients with STEMI: Executive summary. JACC 2004; 44: 671–719
  • McNamara R. L., Herrin J., Bradley E. H., Portnay E. L., Curtis J. P., Wang Y., Magid D. J., Blaney M., Krumholz H. M., for the NRMI Investigators. Hospital Improvement in Time to Reperfusion in Patients With Acute Myocardial Infarction, 1999 to 2002. J Am Coll Cardiol 2006; 47: 45–51
  • Gibson C. M. Time is myocardium and time is outcomes. Circulation 2001; 104: 2632
  • Cannon C. P., Gibson M., Tambrew C. T., Shoultz D. A., Levy D., French W., Gore J. M., Weaver W. D., Rogers W. J., Tiefenbrunn A. J. Relationship of symptom onset to balloon time and door to balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA 2000; 283: 2941–7
  • McNamara R. L., Wang Y., Herrin J., Curtis J. P., Bradley E. H., Magid D. J., Peterson E. D., Blaney M., Frederick P. D., Krumholz H. M. NRMI Investigators Effect of door‐to‐balloon time on mortality in patients with ST‐segment elevation myocardial infarction. J Am Coll Cardiol 2006 Jun 6; 47((11))2180–6
  • Moscucci M., Eagle K. A. Reducing the door‐to‐balloon time for myocardial infarction with ST segment elevation. NEJM 2006; 355((22))2364–5
  • Ortolani P., Marzocchi A., Marrozzini C., et al. Clinical impact of direct referral to primary percutaneous coronary intervention following pre‐hospital diagnosis of ST‐elevation myocardial infarction. Eur Heart J 2006; 27: 1550–1557
  • Vivek Dhruva N., Samir Abdelhadi I., Ather Anis, William Gluckman, David Hom, William Dougan, Edo Kaluski, Bunyad Haider, Marc Klapholz. JACC Aug; 50((6))509–13
  • Hasin Y., Danchin N., Filippatos G. S., Heras M., Janssens U., Leor J., Nahir M., Parkhomenko A., Thygesen K., Tubaro M., Wallentin L. C., Zakke I., Working Group on Acute Cardiac Care of the European Society of Cardiology. Recommendations for the structure, organization, and operation of intensive cardiac care units. Eur Heart J 2005 Aug; 26((16))1676–82
  • Cristofini P., Leizorovicz A., Touboul P. Comparison of Angioplasty and Prehospital Thrombolysis In acute Myocardial infarction (CAPTIM) Investigators. Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial. Circulation 2003 Dec 9; 108((23))2851–6

References

  • The ASSENT‐4 PCI Investigators. Primary versus tenecteplase‐facilitated percutaneous coronary intervention in patients with ST‐segment elevation acute myocardial infarction (ASSENT‐4 PCI): Randomized trial. Lancet 2006; 367: 569–578
  • Keeley E. C., Boura J. A., Grines C. L. Comparison of primary and facilitated percutaneous coronary interventions for ST‐elevation myocardial infarction: quantitative review of randomised trials. Lancet 2006; 367: 579–88
  • Ellis S. G., Da Silva E. R., Spaulding C. M., Nobuyoshi M., Weiner B., Talley J. D. Review of immediate angioplasty after fibrinolytic therapy for acute myocardial infarction: insights from the RESCUE I, RESCUE II, and other contemporary clinical experiences. Am Heart J 2000; 139: 1046–53
  • Sutton A. G., Campbell P. G., Graham R., et al. A randomized trial of rescue angioplasty versus a conservative approach for failed fibrinolysis in ST‐segment elevation myocardial infarction: the Middlesbrough Early Revascularization to Limit Infarction (MERLIN) trial. J Am Coll Cardiol 2004; 44: 287–96
  • Anthony H., Gershlick A. H., Amanda Stephens‐Lloyd A., , for the REACT Trial Investigators, et al. Rescue Angioplasty after Failed Thrombolytic Therapy for Acute Myocardial Infarction. N Engl J Med 2005; 353: 2758–68
  • Miller J. M., Smalling R., Ohman E. M., et al. Effectiveness of early coronary angioplasty and abciximab for failed thrombolysis (reteplase or alteplase) during acute myocardial infarction (results from the GUSTO‐III trial). Global Use of Strategies To Open Occluded Coronary Arteries. Am J Cardiol 1999; 84: 779–84
  • Petronio A. S., Musumeci G., Limbruno U., et al. Abciximab improves 6‐month clinical outcome after rescue coronary angioplasty. Am Heart J 2002; 143: 334–41
  • Cantor W. J., Kaplan A. L., Velianou J. L., et al. Effectiveness and safety of abciximab after failed thrombolytic therapy. Am J Cardiol 2001; 87: 439–42

References

  • Chen Z. M., Jiang L. X., Chen Y. P., Xie J. X., Pan H. C., Peto R., Collins R., Liu L. S. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo‐controlled trial. Lancet 2005; 366: 1607–21
  • Sabatine M. S., Cannon C. P., Gibson C. M., Lopez‐Sendon J. L., Montalescot G., Theroux P., Claeys M. J., Cools F., Hill K. A., Skene A. M., McCabe C. H., Braunwald E. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST‐segment elevation. N Engl J Med 2005; 352: 1179–89
  • Yusuf S., Zhao F., Mehta S. R., Chrolavicius S., Tognoni G., Fox K. K. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST‐segment elevation. N Engl J Med 2001; 345: 494–502
  • Bassand J. P., Hamm C. W., Ardissino D., Boersma E., Budaj A., Fernandez‐Aviles F., Fox K. A., Hasdai D., Ohman E. M., Wallentin L., Wijns W., Vahanian A., Camm J., De Caterina R., Dean V., Dickstein K., Filippatos G., Kristensen S. D., Widimsky P., McGregor K., Sechtem U., Tendera M., Hellemans I., Gomez J. L., Silber S., Funck‐Brentano C., Kristensen S. D., Andreotti F., Benzer W., Bertrand M., Betriu A., De Caterina R., Desutter J., Falk V., Ortiz A. F., Gitt A., Hasin Y., Huber K., Kornowski R., Lopez‐Sendon J., Morais J., Nordrehaug J. E., Silber S., Steg P. G., Thygesen K., Tubaro M., Turpie A. G., Verheugt F., Windecker S. Guidelines for the diagnosis and treatment of non‐ST‐segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non‐ST‐Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J 2007; 28: 1598–660
  • De Caterina R., Husted S., Wallentin L., Agnelli G., Bachmann F., Baigent C., Jespersen J., Kristensen S. D., Montalescot G., Siegbahn A., Verheugt F. W., Weitz J. Anticoagulants in heart disease: current status and perspectives. Eur Heart J 2007; 28: 880–913
  • Yusuf S., Mehta S. R., Chrolavicius S., Afzal R., Pogue J., Granger C. B., Budaj A., Peters R. J., Bassand J. P., Wallentin L., Joyner C., Fox K. A. Effects of fondaparinux on mortality and reinfarction in patients with acute ST‐segment elevation myocardial infarction: the OASIS‐6 randomized trial. Jama 2006; 295: 1519–30

References

  • Birnbaum Y., Herz I., Sclarovsky S., Zlotikamien B., Chetrit A., Olmer L., Barbash G. I. Prognostic significance of the admission electrocardiogram in acute myocardial infarction. J Am Coll Cardiol 1996; 27: 1128–32
  • Birnbaum Y., Goodman S., Barr A., Gates K. B., Barbash G. I., Battler A., Barbagelata A., Clemmensen P., Sgarbossa E. B., Granger C. B., Califf R. M., Wagner G. S. Comparison of primary coronary angioplasty versus thrombolysis in patients with ST‐segment elevation acute myocardial infarction and grade II and grade III myocardial ischemia on the enrollment electrocardiogram. Am J Cardiol 2001; 88: 842–7
  • Buber J., Gilutz H., Birnbaum Y., Friger M., Ilia R., Zahger D. Grade 3 ischemia on admission and absence of prior beta‐blockade predict failure of ST resolution following thrombolysis for anterior myocardial infarction. Int J Cardiol 2005; 104: 131–7
  • de Lemos J. A., Braunwald E. ST segment resolution as a tool for assessing the efficacy of reperfusion therapy. J Am Coll Cardiol 2001; 38: 1283–94
  • Matetzky S., Novikov M., Gruberg L., Freimark D., Feinberg M., Elian D., Novikov I., Di Segni E., Agranat O., Har‐Zahav Y., Rabinowitz B., Kaplinsky E., Hod H. The significance of persistent ST elevation versus early resolution of ST segment elevation after primary PTCA. J Am Coll Cardiol 1999; 34: 1932–8
  • Wolak A., Yaroslavtsev S., Amit G., Birnbaum Y., Cafri C., Atar S., Ilia R., Zahger D. Grade 3 Ischemia on the Admission Electrocardiogram Predicts Failure of ST Resolution Following Primary Angioplasty for Acute Myocardial Infarction. Am Heart J 2007; 153: 410–417

References

  • Bonderman D., Temi A., Jakowitsch J., et al. Coronary no‐reflow is caused by shedding of active tissue factor from dissected atherosclerotic plaque. Blood 220; 99: 2794–2800
  • Galiuto L., Lombardo A., Maseri A., Santoro L., Porto L., Cianflone D., Rebuzzi A. G., Crea F. Temporal evolution and functional outcome of no reflow: sustained and spontaneously reversible patterns following successful coronary recanalization. Heart 2003; 89: 731–737
  • Thiele H., Kappi M. J., Linke A., Erbs S., Boudriot E., Lembcke A., Kivelitz D., Schuler G. Influence of time to treatment, TIMI‐flow grades, and ST segment resolution on infarct size and infarct transmurality as assessed by delayed enhancement magnetic resonance imaging. Eur Heart J 2007; 28: 1433–1439
  • Gibson C. M. The time‐dependent open vasculature hypothesis. Cardiology Rounds 2000; 4: 10
  • Mahnken A. H., Koos R., Katoh M., et al. Assessment of myocardial viability in reperfused acute myocardial infarction using 16‐slice computed tomography in comparison to magnetic resonance imaging. J Am Coll Cardiol 2005; 45: 204202047
  • Moir S., Haluska B., Leung D., Lim R., Garrahy P., Marwick T. H. Quantitative myocardial contrast echocardiography for prediction of Thrombolysis In Myocardial Infarction (TIMI) flow in acute myocardial infarction. Am J Cardiol 2004; 93: 1212–1217
  • Kaul S., Ito H. Microvasculature in acute myocardial infarction. Part 1. Circulation 2003; 109: 146–149
  • Kaul S., Ito H. Microvasculature in acute myocardial infarction. Part 2. Circulation 2003; 109: 310–315
  • Iwakura K., Ito H., Takiuchi S., Taniyama Y., et al. Alternation in the coronary blood flow velocity pattern in patients with no reflow and reperfused acute myocardial infarction. Circulation 1996; 94: 1269–1275
  • Koyama Y., Matsuoka H., Mochizuki T., et al. Assessment of reperfused acute myocardial infarction with two‐phase contrast‐enhanced helical CT : prediction of left ventricular function and wall thickness. Radiology 2005; 235: 804–811
  • Raff G. L., O'Neill W. W., Gentry R. E., et al. Microvascular obstruction and myocardial function after acute myocardial infarction: Assessment by using contrast‐enhanced cine MR imaging. Radiology 2006; 240: 2: 529–536
  • Galiuta L., Crea F. No‐reflow: A heterogeneous clinical phenomenon with multiple therapeutic strategies. Curr Pharm Design 2006; 12: 3807–3815

References

  • Bassand J. P., Hamm C. W., Ardissino D., Boersma E., Budaj A., Fernandez‐Aviles F., Fox K. A., Hasdai D., Ohman E. M., Wallentin L., Wijns W. Guidelines for the diagnosis and treatment of non‐ST‐segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non‐ST‐Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J 2007; 28((13))1598–660, Epub 2007 Jun 14

References

  • Kris‐Etherton P. M., Harris W. S., Appel L. J. Omega‐3 fatty acids and cardiovascular disease: new recommendations from the American Heart Association. Arterioscler Thromb Vasc Biol 2003; 23: 151–2
  • Middaugh J. P. Cardiovascular deaths among Alaskan Natives, 1980–86. Am J Public Health 1990; 80: 282–5
  • Newman W. P., Middaugh J. P., Propst M. T., Rogers D. R. Atherosclerosis in Alaska Natives and non‐natives. Lancet 1993; 341: 1056–7
  • Erkkila A. T., Lichtenstein A. H., Mozaffarian D., Herrington D. M. Fish intake is associated with a reduced progression of coronary artery atherosclerosis in postmenopausal women with coronary artery disease. Am J Clin Nutr 2004; 80: 626–32
  • Sacks F. M., Stone P. H., Gibson C. M., Silverman D. I., Rosner B., Pasternak R. C. Controlled trial of fish oil for regression of human coronary atherosclerosis. HARP Research Group. J Am Coll Cardiol 1995; 25: 1492–8
  • von Schacky C., Angerer P., Kothny W., Theisen K., Mudra H. The effect of dietary omega‐3 fatty acids on coronary atherosclerosis. A randomized, double‐blind, placebo‐controlled trial. Ann Intern Med 1999; 130: 554–62
  • Angerer P., von Schacky C. n‐3 polyunsaturated fatty acids and the cardiovascular system. Curr Opin Lipidol 2000; 11: 57–63
  • Eritsland J., Arnesen H., Gronseth K., Fjeld N. B., Abdelnoor M. Effect of dietary supplementation with n‐3 fatty acids on coronary artery bypass graft patency. Am J Cardiol 1996; 77: 31–6
  • Maresta A., Balduccelli M., Varani E., Marzilli M., Galli C., Heiman F., Lavezzari M., Stragliotto E., De Caterina R. Prevention of postcoronary angioplasty restenosis by omega‐3 fatty acids: main results of the Esapent for Prevention of Restenosis ITalian Study (ESPRIT). Am Heart J 2002; 143: E5
  • Balk E. M., Lichtenstein A. H., Chung M., Kupelnick B., Chew P., Lau J. Effects of omega‐3 fatty acids on coronary restenosis, intima‐media thickness, and exercise tolerance: a systematic review. Atherosclerosis 2006; 184: 237–46
  • Yokoyama M., Origasa H. Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS). Am Heart J 2003; 146: 613–20
  • Yokoyama M., for the Japan EPA Lipid Intervention Study (JELIS) Group. Effects of eicosapentaenoic acid (EPA) on major cardiovascular events in hypercholesterolemic patients. Circulation 2005, American Heart Association Scientific Sessions, Dallas, TX, Nov 13–16:(Abstract)
  • Leaf A., Weber P. C. Cardiovascular effects of n‐3 fatty acids. N Engl J Med 1988; 318: 549–57
  • Harris W. S. n‐3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr 1997; 65: 1645S–1654S
  • Endres S., Ghorbani R., Kelley V. E., Georgilis K., Lonnemann G., van der Meer J. W., Cannon J. G., Rogers T. S., Klempner M. S., Weber P. C., et al. The effect of dietary supplementation with n‐3 polyunsaturated fatty acids on the synthesis of interleukin‐1 and tumor necrosis factor by mononuclear cells. N Engl J Med 1989; 320: 265–71
  • Fox P. L., DiCorleto P. E. Fish oils inhibit endothelial cell production of platelet‐derived growth factor‐like protein. Science 1988; 241: 453–6
  • Kaminski W. E., Jendraschak E., Kiefl R., von Schacky C. Dietary omega‐3 fatty acids lower levels of platelet‐derived growth factor mRNA in human mononuclear cells. Blood 1993; 81: 1871–9
  • Hansen J. B., Olsen J. O., Wilsgard L., Osterud B. Effects of dietary supplementation with cod liver oil on monocyte thromboplastin synthesis, coagulation and fibrinolysis. J Intern Med Suppl 1989; 731: 133–9
  • Shimokawa H., Vanhoutte P. M. Dietary omega 3 fatty acids and endothelium‐dependent relaxations in porcine coronary arteries. Am J Physiol 1989; 256: H968–73
  • Baumann K. H., Hessel F., Larass I., Muller T., Angerer P., Kiefl R., von Schacky C. Dietary omega‐3, omega‐6, and omega‐9 unsaturated fatty acids and growth factor and cytokine gene expression in unstimulated and stimulated monocytes. A randomized volunteer study. Arterioscler Thromb Vasc Biol 1999; 19: 59–66
  • De Caterina R., Massaro M. Omega‐3 fatty acids and the regulation of expression of endothelial pro‐atherogenic and pro‐inflammatory genes. J Membr Biol 2005; 206: 103–16
  • Massaro M., Habib A., Lubrano L., Del Turco S., Lazzerini G., Bourcier T., Weksler B. B., De Caterina R. The omega‐3 fatty acid docosahexaenoate attenuates endothelial cyclooxygenase‐2 induction through both NADP(H) oxidase and PKC epsilon inhibition. Proc Natl Acad Sci U S A 2006; 103: 15184–9

References

  • Hirsch A., et al. Long‐term outcome after an early invasive versus selective invasive treatment strategy in patients with non‐ST‐elevation acute coronary syndrome and elevated cardiac troponin T (the ICTUS trial): a follow‐up study. Lancet 2007; 369: 827
  • disinter R. J., et al. Invasive versus conservative treatment in unstable coronary syndromes (ICTUS) investigators. NEJM 2005; 353: 1095
  • Fox K. A., et al. 5‐year outcome of an interventional strategy in non‐ST‐elevation acute coronary syndrome: the British Heart Foundation RITA 3 randomised trial. Lancet 2005; 365: 914
  • Choudhry N. K., et al. How should patients with unstable angina and non‐ST‐segment elevation myocardial infarction be managed? A meta‐analysis of randomized trials. Am J Med 2005; 118: 485
  • Mehta S. R., et al. Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta‐analysis of randomized trials. JAMA 2005; 293: 2908
  • Clayton T. C., et al. Do men benefit more than women from an interventional strategy in patients with unstable angina or non‐ST‐elevation myocardial infarction? The impact of gender in the RITA 3 trial. Eur Heart J 2004; 25: 1641

References

  • Boden W. E., O'Rourke R. A., Crawford M. H., Blaustein A. S., Deedwania P. C., Zoble R. G., Wexler L. F., Kleiger R. E., Pepine C. J., Ferry D. R., Chow B. K., Lavori P. W. Outcomes in patients with acute non‐Q‐wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non‐Q‐Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators. N Engl J Med 1998; 338: 1785–1792
  • Braunwald E., Antman E. M., Beasley J. W., et al. ACC/AHA Guideline Update for the Management of Patients With Unstable Angina and Non–ST‐Segment Elevation Myocardial Infarction—2002: Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation 2002; 106: 1893–1900
  • Fragmin and Fast Revascularisation during InStability in Coronary artery disease (FRISC‐II) investigators. Invasive compared with non‐invasive treatment in unstable coronary‐artery disease. FRISC‐II prospective randomized multicentre study. Lancet 1999; 354: 708–715
  • TACTICS‐Thrombolysis in Myocardial Infarction‐18 investigators, Cannon C. P., Weintraub W. S., Demopoulos L. A., et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001; 344: 1879–1887
  • Randomized Intervention Trial of unstable Angina investigators, Fox K. A., Poole‐Wilson P. A., Henderson R. A., et al. Interventional versus conservative treatment for patients with unstable angina or non‐ST‐elevation myocardial infarction: the British Heart Foundation RITA‐3 randomized trial. Randomized Intervention Trial of unstable Angina. Lancet 2002; 360: 743–751
  • de Winter R. J., Windhausen F., Cornel J. H., Dunselman P. H., Janus C. L., Bendermacher P. E., Michels H. R., Sanders G. T., Tijssen J. G., Verheugt F. W. Early invasive versus selectively invasive management for acute coronary syndromes. N Engl J Med 2005; 353: 1095–1104
  • Mehta S. R., Cannon C. P., Fox K. A., et al. Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta‐analysis of randomized trials,. JAMA 2005; 293: 2908–291
  • Bavry A. A., Kumbhani D. J., Rassi A. N., Bhatt D. L., Askari A. T. Benefit of early invasive therapy in acute coronary syndromes: A meta‐analysis of contemporary randomized clinical trials,. J Am Coll Cardiol 2006; 48: 1319–1325
  • Hoenig M. R., Doust J. A., Aroney C. N., Scott I. A. Early invasive versus conservative strategies for unstable angina & non‐ST‐elevation myocardial infarction in the stent era. Cochrane Database of Systematic Reviews 2006, Issue 3. Art. No.: CD004815
  • Authors/Task Force Members, Jean‐Pierre Bassand, Christian Hamm W., Diego Ardissino, et al. Guidelines for the diagnosis and treatment of non‐ST‐segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non‐ST‐Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J 2007; 28: 1598–1660

References

  • Sabatine M. S., Morrow D. A., Giugliano R. P., et al. Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation 2005; 111: 2042–2049
  • Nikolsky E., Aymong E. D., Halkin A., et al. Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial. J Am Coll Cardiol 2004; 44: 547–553
  • Moscucci M., Fox K. A., Cannon C. P., et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2003; 24: 1815–1823
  • Alexander K. P., Chen A. Y., Roe M. T., et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non‐ST‐segment elevation acute coronary syndromes. Jama 2005; 294: 3108–3116
  • Aronson D., Suleiman M., Agmon Y., et al. Changes in haemoglobin levels during hospital course and long‐term outcome after acute myocardial infarction. Eur Heart J 2007; 28: 1289–1296
  • Rao S. V., Eikelboom J. A., Granger C. B., et al. Bleeding and blood transfusion issues in patients with non‐ST‐segment elevation acute coronary syndromes. Eur Heart J 2007
  • Eikelboom J. W., Mehta S. R., Anand S. S., et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006; 114: 774–782
  • Rao S. V., Jollis J. G., Harrington R. A., et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 2004; 292: 1555–1562
  • Wu W. C., Rathore S. S., Wang Y., et al. Blood transfusion in elderly patients with acute myocardial infarction. N Engl J Med 2001; 345: 1230–1236
  • Yang X., Alexander K. P., Chen A. Y., et al. The implications of blood transfusions for patients with non‐ST‐segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative. J Am Coll Cardiol 2005; 46: 1490–1495

References

  • Choay J., Petitou M., Lormeau J. C., et al. Structure‐activity relationship in heparin: asynthetic pentasaccharide with high affinity for antithrobin and eliciting high anti‐factor Xa activity. Biochem Biophys Res Comm 1983; 116: 492–499
  • Boneu B., Necciari J., Cariou R., et al. pharmacokinetics and tolerance of the natural pentasaccharide (SR 90107/ORG 31540) with high affinity to antithrombin III in man. Thromb Haemost 1995; 74: 1468–1473
  • Walenga J. M., Bara L., Petitou M., et al. The inhibition of the generation of thrombin and the antithrombotic effect of a pentasaccharide with sole anti‐factor Xa activity. Thromb Res 1988; 51: 23–33
  • Warkentin T. E., Greinacher A. Heparin‐induced thrombocytopenia:recognition, treatment and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 311S–337S
  • Lassen M. R., Bauer K. A., Eriksson B. I. Postoperative fondaparinux versus preoperative enoxaparin for prevention of VTE in elective hip‐replacement surgery: randomized double‐blind comparison. Lancet 2002; 359: 1715–1720
  • Turpie A. G. G., Bauer K. A., Eriksson B. I., et al. For the pentathlon 2000 study steering committee . Postoperative fondaparinux versus postoperative enoxaparin for the prevention of venous thromboembolism after elective hip‐replacement surgery: a randomized double blind trial. Lancet 2002; 359: 1721–1726
  • Bauer ka, Eriksson B. I., Lassen M. R. for the Steering committee of the Pentasaccharide in major knee surgery study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N. Engl Med 2001; 345: 1305–1304
  • Eriksson B. I., bauer K. A., Lassen M. R., et al. For the Steering committee of the pentasaccharide in hip fracture surgery study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip‐fracture surgery. N Engl J Med 2001; 345: 1298–1304
  • Agneli G., Bergqvist D., Cohen A., , PEGASUS investigators, et al. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high ris abdominal surgery. Br J Surg 2005; 92: 1212–1220
  • Cohen A. T., Davidson B. L., Gallus A. S., et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomized placebo controlled trial.
  • Buller H. R., Davidson B. L., Decousus H., et al. Fomdaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis; a randomized trial. Ann Intern Med 2004; 140: 867–873
  • Buller H. R., Davidson B. L., Decousus H., et al. The MATISSE investigators. Subcutaneous fondaprinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003; 1695–1702, 349

References

  • Cannon C. P., Weintraub W. S., Demopoulos L. A., et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001; 344: 1879–87
  • Antman E. M., McCabe C., Gurkinkel E. P., Turpie A. G., Bernink P. J., Salein D., et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non‐Qwave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999; 100: 1593–601
  • Antman E. M., Cohen M., Radley D., McCabe C., Rush J., Premmereur J., et al. Assessment of the treatment effect of enoxaparin for unstable angina/non‐Q‐wave myocardial infarction. TIMI 11B‐ESSENCE meta‐analysis. Circulation 1999; 100: 1602–8
  • Petersen J. L., Mahaffey K. W., Hasselblad V., et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non‐ST‐segment elevation acute coronary syndromes: a systematic overview. JAMA 2004; 292: 89–96
  • Ferguson J. J., Califf R. M., Antman E. M., et al. Enoxaparin vs unfractionated heparin in high‐risk patients with non‐ST‐segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004; 292: 45–54
  • Rao S. V., O'Grady K., Pieper K. S., Granger C. B., Newby L. K., Van de Werf F., Mahaffey K. W., Califf R. M., Harrington R. A. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol 2005; 96: 1200–1206
  • The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006; 354: 1464–76
  • Hulot J. S., Montalescot G., Lechat P., Collet J. P., Ankri A., Urien S. Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non–ST‐segment elevation acute coronary syndrome. Clin Pharmacol Ther 2005; 77: 542–52
  • Montalescot G., White H. D., Gallo R., et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 2006; 1006–1017, 355

References

  • Gum P., Kottke‐Marchant K., Welsh P. A., White J., Topol E. J. Determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 42((7))1336–1337
  • Matetzky S., Shenkman B., Guetta V., et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation Jun 29 2004; 109((25))3171–3175
  • Frossard M., Fuchs I., Leitner J. M., et al. Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation Sep 14 2004; 110((11))1392–1397
  • Steinhubl S., Talley J., Braden G., et al. Point‐of‐care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event following percutaneous coronary intervention. Results of the GOLD (AU‐Assessing Ultegra) multicenter study. Circulation 2001; 103: 1403–1409
  • Chen W. H., Lee P. Y., Ng W., Tse H. F., Lau C. P. Aspirin resistance is associated with a high incidence of myonecrosis after non‐urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol Mar 17 2004; 43((6))1122–1126
  • Michelson A. D., Barnard M. R., Krueger L. A., Valeri C. R., Furman M. I. Circulating monocyte‐platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P‐selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation Sep 25 2001; 104((13))1533–1537
  • Michelson A. D. Platelet function testing in cardiovascular diseases. Circulation Nov 9 2004; 110((19))e489–493

References

  • Keeley E. C., Boura J. A., Grines C. L. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomized trials. Lancet 2003; 361: 13–20
  • Montalescot G., Barragan P., Wittenberg O., Ecollan P., Elhadad S., Villain P., , ADMIRAL Investigators, et al. Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long‐Term Follow‐up Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001; 344: 1895–1903
  • Montalescot G., Borentain M., Payot L., Collet J. P., Thomas D. Early vs. late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST‐segment elevation myocardial infarction: a meta‐analysis. JAMA 2004; 292: 362–366
  • Keeley E. C., Boura J. A., Grines C. L. Comparison of primary, facilitated percutaneous coronary interventions for ST‐elevation myocardial infarction: quantitative review of randomized trials. Lancet 2006; 367: 579–588
  • Gibson C. M., Kirtane A. J., Murphy S. A., Rohrbeck S., Menon V., Lins J., et al. Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST‐segment elevation myocardial infarction: Results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)‐TIMI 34 trial. Am Heart J 2006; 152: 4, 668–675
  • Maioli M., Bellandi F., Leoncini M., Toso A., Dabizzi R. P. Randomized Early Versus Late Abciximab in Acute Myocardial Infarction Treated With Primary Coronary Intervention (RELAx‐AMI Trial). JACC 2007; 49: 14, 1517–1524
  • van't Hof A. W., Ernst N., de Boer M. J., de Winter R., Boersma E., Bunt T., et al. Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On‐TIME) trial. Eur Heart J 2004; 25: 837–846
  • Clinicaltrials.gov NCT00046228, FINESSE
  • Kiernan T. H., Ting H. H., Gersh B. J. Facilitated percutaneous coronary intervention: current concepts, promises, and pitfalls. Eur Heart J 2007; 28: 1545–1553

References

  • Sabatine M. S., Cannon C. P., Gibson C. M., et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST‐segment elevation. N Engl J Med 2005; 352: 1179–1189
  • Sabatine M. S., Cannon C. P., Gibson C. M., et al. Clopidogrel as Adjunctive Reper‐ fusi on Therapy (CLARITY)‐Thrombol ysi s i n Myocardi al Infarcti on (TIMI) 28 Investigators. Effect of clopidogrel pretreatment before percutaneous coronary in‐ tervention in patients with ST‐elevation myocardial infarction treated with fibri‐ nolytics: the PCI‐CLARITY study. JAMA 2005; 294: 1224–1232
  • Mehta S. R., Yusuf S., Peters R., et al. Effects of pretreatment with clopidogrel and aspirin followed by long‐term therapy in patients undergoing percutaneous coronary intervention: the PCI‐CURE study. Lancet 2001; 358: 527–533
  • Steinhubl S. R., Berger P. B., Mann J. T., , for the CREDO Investigators, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. A randomized controlled trial. JAMA 2002; 288((19))2411–2420
  • COMMIT Collaborative Group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo‐controlled trial. Lancet 2005; 366: 1607–1621

References

  • Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST‐segment elevation. N Engl J Med 2001; 345: 494–502
  • Mehta S. R., Yusuf S., Peters R. J. G., Bertrand M. E., Lewis B. S., Natarajan M. K., Malmberg K., Rupprecht H. ‐. J., Zhao F., Chrolavicius S., Copland I., Fox K. A. A., for the Clopidigrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long‐term therapy in patients undergoing percutaneous coronary intervention: the PCI‐CURE study. Lancet 2001; 358: 527–533
  • Berger P. B., Dzavik V., Penn I. M., Catellier D., Buller C. E., for the TOSCA Investigators. Does ticlopidine reduce reocclusion and other adverse events after successful balloon angioplasty of occluded coronary arteries?
  • Steinhubl S. R., Berger P. B., Mann J. T., , for the CREDO Investigators, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. A randomized controlled trial. JAMA 2002; 288: 2411–2420
  • Bernardi V., Szerfer J., Summay G., et al. Long‐term versus short‐term Clopidogrel therapy in patients undergoing coronary stenting (from the Randomized Argentine Clopidogrel Stent [RACS] Trial). Am J Cardiol 2007; 99((3))349–52
  • Grines C. L., Bonow R. O., Casey D. E., et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents. A science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, With Representation From the American College of Physicians. Circulation 2007; 115, &NA;‐.)
  • Bhatt D. L., Fox K. A., Hacke W., , for the CHARISMA Investigators, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. New Engl J Med 2005; 354((16))1706–1717

References

  • Brandt J. T., Payne C. D., Wiviott S. D., et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 2007 Jan; 153((1))66.e9–16
  • Greenbaum A. B., Grines C. L., Bittl J. A., et al. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2‐part, phase II, multicenter, randomized, placebo‐ and active‐controlled trial. Am Heart J 2006 Mar; 151((3))689.e1–689.e10
  • Wiviott S. D., Antman E. M., Winters K. J., et al. Randomized comparison of prasugrel (CS‐747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)‐TIMI 26 trial. Circulation 2006 Jun 28; 111((25))3366–73
  • Tantry U. S., Bliden K. P., Gurbel P. A. AZD6140. Expert Opin Investig Drugs 2007 Feb; 16((2))225–9
  • Wu C. C., Teng C. M. Comparison of the effects of PAR1 antagonists, PAR4 antagonists, and their combinations on thrombin‐induced human platelet activation. Eur J Pharmacol 2006 Sep 28; 546((1–3))142–7

References

  • Hasdai D., Haim M., Behar S., Boyko V., Battler A. Acute coronary syndromes in patients with prior cerebrovascular events: lessons from the Euro‐Heart Survey of Acute Coronary Syndromes. Am Heart J 2003 Nov; 146((5))832–8
  • Iakobishvili Z., Feinberg M. S., Danicek V., Behar S., Zahger D., Hod H., Sandach A., Hammerman H., Sagie A., Mager A., Gottlieb S., Hasdai D., Israeli ACSIS 2004 Investigators. Prior heart failure among patients with acute coronary syndromes is associated with a higher incidence of in‐hospital heart failure. Acute Card Care 2006; 8((3))143–7
  • Hasdai D., Lev E. I., Behar S., Boyko V., Danchin N., Vahanian A., Battler A. Acute coronary syndromes in patients with pre‐existing moderate to severe valvular disease of the heart: lessons from the Euro‐Heart Survey of acute coronary syndromes. Eur Heart J 2003 Apr; 24((7))623–9
  • Iakobishvili Z., Eisen A., Porter A., Cohen N., Abramson E., Mager A., Shapira Y., Sagie A., Battler A., Hasdai D. Acute coronary syndromes in patients with prosthetic heart valves – A case series., Submitted

References

  • Grundy S. M., Cleeman J. I., Bairey Merz C. N., et al. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004; 110: 227–239
  • Chan P. S., Nallamothu B. K., Gurm H. S., Hayward R. A., Vijan S. Incremental benefit and cost‐effectiveness of high‐dose statin therapy in high‐risk patients with coronary artery disease. Circulation 2007; 115: 2398–409
  • Brewer H. B. Benefit‐risk assessment of Rosuvastatin 10 to 40 milligrams. Am J Cardiol 2003; 92: 23K–29K
  • de Lemos J. A., Blazing M. A., Wiviott S. D., et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004; 15: 1307–16
  • Newman C., Tsai J., Szarek M., Luo D., Gibson E. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Am J Cardiol 2006; 97: 61–7
  • Davidson M. H., Robinson J. G. Safety of aggressive lipid management. J Am Coll Cardiol 2007; 49: 1753–62
  • Pasternak R. C., Smith S. C., Bairey‐Merz C. N., et al. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Circulation 2002; 106: 1024
  • Kashani A., Phillips C. O., Foody J. M., Wang Y., Mangalmurti S., Ko D. T., Krumholz H. M. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 2006; 114: 2788–97
  • Harper C. R., Jacobson T. A. The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis. Curr Opin Lipidol 2007; 18: 401–8

References

  • Cannon C. P., Braunwald E., McCabe C. H., et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction‐22 Investigators Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495–1504
  • Nissen S. E., Tuzcu E. M., Schoenhagen P., et al. Effect of intensive compared with moderate lipid‐lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004; 291: 1071–1080
  • Nissen S. E., Tuzcu E. M., Schoenhagen P., Crowe T., Sasiela W. J., Tsai J., Orazem J., Magorien R. D., O'Shaughnessy C., Ganz P. Statin therapy, LDL cholesterol, C‐reactive protein, and coronary artery disease. N Engl J Med 2005; 352: 29–38
  • Nissen S. E., Nicholls S. J., Sipahi I., et al. Effect of very high‐intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006; 295: 1556–1565
  • LaRosa J. C., Grundy S. M., Waters D. D., et al. Treating to New Targets Investigators Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425–1435
  • de Lemos J. A., Blazing M. A., Wiviott S. D., et al. A‐to‐Z Investigators Early intensive vs. a delayed conservative simvastatin strategy in patients with acute coronary syndromesphase Z of the A‐to‐Z trial. JAMA 2004; 292: 1307–1316
  • Pedersen T. R., Faergeman O., Kastelein J. J., et al. Incremental Decrease in End Points Through Aggressive Lipid‐Lowering Study Group High‐dose atorvastatin versus usual‐dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005; 294: 2437–2445
  • Cannon C. P., Steinberg B. A., Murphy S. A., Mega J. L., Braunwald E. Meta‐analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006; 48: 438–445

References

  • Hochman J. S., Buller C. E., Sleeper L. A., Boland J., Dzavik V., Sanborn T. A., Godfrey E., White H. D., Lim J., LeJemtel T. Cardiogenic shock complicating acute myocardial infarction—etiologies, management and outcome: a report from the SHOCK Trial Registry. Should we emergently revascularize Occluded Coronaries for cardiogenic shocK?. J Am Coll Cardiol 2000; 36((3 Suppl A))1063–70
  • Moreno P. R., Jang I. K., Newell J. B., Block P. C., Palacios I. F. The role of percutaneous aortic balloon valvuloplasty in patients with cardiogenic shock and critical aortic stenosis. J Am Coll Cardiol 1994; 23: 1071–5
  • Mann T., McLaurin L., Grossman W., Craige E. Assessing the hemodynamic severity of acute aortic regurgitation due to infective endocarditis. N Engl J Med 1975; 293: 108–13
  • Horstkotte D., Schulte H. D., Niehues R., Klein R. M., Piper C., Strauer B. E. Diagnostic and therapeutic considerations in acute, severe mitral regurgitation: experience in 42 consecutive patients entering the intensive care unit with pulmonary edema. J Heart Valve Dis 1993; 2: 512–22
  • Wu J. J., Chern M. S., Yeh K. H., Chen Y. C., Fu M., Hung J. S. Urgent/emergent percutaneous transvenous mitral commissurotomy. Cathet Cardiovasc Diagn 1994; 31: 18–22
  • American College of Cardiology/American Heart Association Task Force on Practice Guidelines Society of Cardiovascular Anesthesiologists Society for Cardiovascular Angiography and Interventions Society of Thoracic Surgeons, Bonow R. O., Carabello B. A., Kanu C., de Leon A. C., Jr., Faxon D. P., Freed M. D., Gaasch W. H., Lytle B. W., Nishimura R. A., O'Gara P. T., O'Rourke R. A., Otto C. M., Shah P. M., Shanewise J. S., Smith S. C., Jr., Jacobs A. K., Adams C. D., Anderson J. L., Antman E. M., Faxon D. P., Fuster V., Halperin J. L., Hiratzka L. F., Hunt S. A., Lytle B. W., Nishimura R., Page R. L., Riegel B. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation 2006; 114: e84–231
  • Vahanian A., Baumgartner H., Bax J., Butchart E., Dion R., Filippatos G., Flachskampf F., Hall R., Iung B., Kasprzak J., Nataf P., Tornos P., Torracca L., Wenink A., Priori S. G., Blanc J. J., Budaj A., Camm J., Dean V., Deckers J., Dickstein K., Lekakis J., McGregor K., Metra M., Morais J., Osterspey A., Tamargo J., Zamorano J. L., Zamorano J. L., Angelini A., Antunes M., Fernandez M. A., Gohlke‐Baerwolf C., Habib G., McMurray J., Otto C., Pierard L., Pomar J. L., Prendergast B., Rosenhek R., Uva M. S., Tamargo J. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 2007; 28: 230–68

References

  • Nieminen M., Bohn M., Cowie R. M., Drexler H., Filippatos S. G., Jondeau G., Hasin Y., Lopez‐Sendon J., Mebazaa A., Metra M., Rhodes A., Swedberg K. “Executive Summary of the Guidelines on the Diagnosis and Treatment of Acute Heart Failure”.The Task Force on AHF of the European Society of Cardiology. European Heart Journal 2005; (26): 384–416
  • Costachescu T., Denault A., Guimond J. G., Couture P., Carignan S., Sheridan P., Hellou G., Blair L., Normandin L., Babin D., Allard M., Harel F., Buithieu J. The hemodynamically unstable patient in the intensive care unit: hemodynamic vs. transesophageal echocardiographic monitoring. Crit Care Med 2002; 30: 1214–23
  • Kim R., Chakko S., Myerburg R. J., Kessler K. M. Clinical usefulness and cost of echocardiography in patients admitted to a coronary care unit. Am J Cardiol 1997 Nov 15; 80: 1273–6
  • Romano S., Varveri A., Aurigemma G., Dagianti A., Vitarelli A., Sciomer S., Pastore L. R., Penco M., Dagianti A. Echocardiography in the coronary care unit: diagnostic and prognostic impact in comparison with clinical and other indicators. Am J Cardiol 1998 18; 81((12A))13G–16G
  • Berkowitz M. J., Picard M. H., Harkness S., Sanborn T. A., Hochman J. S., Slater J. N. Echocardiographic and angiographic correlations in patients with cardiogenic shock secondary to acute myocardial infarction. Am J Cardiol 2006 15; 98: 1004–8
  • Joseph M. X., Disney P. J., Da Costa R., Hutchison S. J. Transthoracic echocardiography to identify or exclude cardiac cause of shock. Chest 2004 Nov; 126((5))1592–7
  • Hochman J. S., Buller C. E., Sleeper L. A., Boland J., Dzavik V., Sanborn T. A., Godfrey E., White H. D., Lim J., LeJemtel T. Cardiogenic shock complicating acute myocardial infarction–etiologies, management and outcome: a report from the SHOCK Trial Registry. Should we emergently revascularize Occluded Coronaries for cardiogenic shock?. J Am Coll Cardiol 2000; 36((3 Suppl A))1063–70
  • Goldman J. H., Slade A., Clague J. Cardiogenic shock secondary to mitral stenosis treated by balloon mitral valvuloplasty. Cathet Cardiovasc Diagn 1998; 43: 195–7
  • Moreno P. R., Jang I. K., Newell J. B., Block P. C., Palacios I. F. The role of percutaneous aortic balloon valvuloplasty in patients with cardiogenic shock and critical aortic stenosis. J Am Coll Cardiol 1994; 23: 1071–5
  • Shareghi S., Rasouli L., Shavelle D. M., Burstein S., Matthews R. V. Current results of balloon aortic valvuloplasty in high‐risk patients. J Invasive Cardiol 2007 Jan; 19((1))1–5

References

  • Tawn Z., Himbert D., Brochet E., Messika‐Zeitoun D., Iung B., Vahanian A. Percutaneous valve procedures: present and future. Int J Cardiovasc Intervent 2005; 7: 14–20
  • Cribier A., Eltchaninoff H., Bash A., Borenstein N., Tron C., Bauer F., Derumeaux G., Anselme F., Laborde F., Leon M. B. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation 2002; 106: 3006–8
  • Webb J. G., Chandavimol M., Thompson C. R., Ricci D. R., Carere R. G., Munt B. I., Buller C. E., Pasupati S., Lichtenstein S. Percutaneous aortic valve implantation retrograde from the femoral artery. Circulation 2006; 113: 842–50
  • Grube E., Laborde J. C., Gerckens U., Felderhoff T., Sauren B., Buellesfeld L., Mueller R., Menichelli M., Schmidt T., Zickmann B., Iversen S., Stone G. W. Percutaneous implantation of the CoreValve self‐expanding valve prosthesis in high‐risk patients with aortic valve disease: the Siegburg first‐in‐man study. Circulation 2006; 114: 1616–24
  • Vahanian A., Baumgartner H., Bax J., Butchart E., Dion R., Filippatos G., Flachskampf F., Hall R., Iung B., Kasprzak J., Nataf P., Tornos P., Torracca L., Wenink A., Priori S. G., Blanc J. J., Budaj A., Camm J., Dean V., Deckers J., Dickstein K., Lekakis J., McGregor K., Metra M., Morais J., Osterspey A., Tamargo J., Zamorano J. L., Zamorano J. L., Angelini A., Antunes M., Fernandez M. A., Gohlke‐Baerwolf C., Habib G., McMurray J., Otto C., Pierard L., Pomar J. L., Prendergast B., Rosenhek R., Uva M. S., Tamargo J. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 2007; 28: 230–68
  • Lichtenstein S. V., Cheung A., Ye J., Thompson C. R., Carere R. G., Pasupati S., Webb J. G. Transapical transcatheter aortic valve implantation in humans: initial clinical experience. Circulation 2006; 114: 591–6
  • Feldman T., Wasserman H. S., Herrmann H. C., Gray W., Block P. C., Whiltlow P. L., St. Goar F., Rodriguez L., Silvestry F., Schwartyz A., Sanborn T. A., Condado J. A. Foster E: Percutaneous mitral valve repair using the edge‐to‐edge technique: 6 month results of the EVEREST phase I clinical trial. J Am Coll Cardiol 2005; 46: 2134–40
  • Webb J. G., Harnek J., Munt B. I., Kimblad P. O., Chandavimol M., Thompson C. R., Mayo J. R., Solem J. O. Percutaneous transvenous mitral annuloplasty: initial human experience with device implantation in the coronary sinus. Circulation 2006; 113: 851–5

References

  • Goldberg R. J., Gore J. M., Alpert J. S., et al. Cardiogenic shock after acute myocardial infarction: incidence and mortality from a community‐wide perspective, 1975 to 1988. N Engl J Med 1991; 325: 117–22
  • Hochman J. S., Sleeper L. A., Webb J. G., et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. N Engl J Med 1999; 341: 625–34
  • Hochman J. S., Sleeper L. A., White H. D., et al. One‐year survival following early revascularization for cardiogenic shock. JAMA 2001; 285: 190–2
  • Tayara W., Starling R. C., Yamani M. H., et al. Improved survival after acute myocardial infarction complicated by cardiogenic shock with circulatory support and transplantation: Comparing aggressive intervention with conservative treatment. J Heart Lung Transplant 2006; 25: 504–9
  • Leshnower B. G., Gleason T. G., O'Hara M. L., et al. Safety and efficacy of left ventricular assist device support in postmyocardial infarction cardiogenic shock. Ann Thorac Surg 2006; 81: 1365–71
  • 11. Kherani A. R., Cheema F. H., Oz M. C., et al. Implantation of a left ventricular assist device and the hub‐and‐spoke system in treating acute cardiogenic shock: who survives?. J Thorac Cardiovasc Surg 2003; 126: 1634–5

References

  • Lundberg J. O. Nitric oxide metabolites and cardiovascular disease. J Am Coll Cardiol 2006; 47: 580–1
  • Hochman J. S. Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm. Circulation 2003; 107((24))2998–3002
  • Tada H., Thompson C. I., Recchia F. A., Loke K. E., Ochoa M., Smith C. J., Shesely E. G., Kaley G., Hintze T. H. Myocardial glucose uptake is regulated by nitric oxide via endothelial nitric oxide synthase in Langendorff mouse heart. Circ Res 2000; 86((3))270–4
  • Ziolo M. T., Maier L. S., Piacentino V 3rd., Bossuyt J., Houser S. R., Bers D. M. Myocyte nitric oxide synthase 2 contributes to blunted beta‐adrenergic response in failing human hearts by decreasing Ca2+ transients. Circulation 2004; 109((15))1886–91
  • Traverse J. H., Chen Y., Hou M., Bache R. J. Inhibition of NO production increases myocardial blood flow and oxygen consumption in congestive heart failure. Am J Physiol Heart Circ Physiol 2002 Jun; 282((6))H2278–83
  • Zeymer U., Vogt A., Zahn R., Weber M. A., Tebbe U., Gottwik M., Bonzel T., Senges J., Neuhaus K. L. The Arbeitsgemeinschaft Leitende Kardiologische Krankenhausarzte (ALKK). Predictors of in‐hospital mortality in 1333 patients with acute myocardial infarction complicated by cardiogenic shock treated with primary percutaneous coronary intervention (PCI); Results of the primary PCI registry of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausarzte (ALKK). Eur Heart J 2004; 25((4))322–8
  • Cotter G., Kaluski E., Blatt A., Milovanov O., Moshkovitz Y., Zaidenstein R., Salah A., Alon D., Michovitz Y., Metzger M., Vered Z., Golik A. L‐NMMA (a nitric oxide synthase inhibitor) is effective in the treatment of cardiogenic shock. Circulation 2000; 101((12))1358–61
  • Cotter G., Kaluski E., Milo O., Blatt A., Salah A., Hendler A., Krakover R., Golick A., Vered Z. LINCS: L‐NAME (a NO synthase inhibitor) in the treatment of refractory cardiogenic shock: a prospective randomized study. Eur Heart J 2003; 24((14))1287–95
  • Dzavik V., Cotter G., Farkouh M. E., Ramanathan K., Reynolds H. R., Baran D., Cantor W., Menon V., Kaluski E., Prondzinsky R., Stebbins A., Hochman J. S. Effect of nitric oxide synthase inhibition on hemodynamics and outcome of patients with acute myocardial infarction complicated by cardiogenic shock: a Phase 2 dose‐ranging study. on behalf of the SHOCK‐2 Investigators American Heart Association Scientific Sessions, November 8, 2004

References

  • Cohen M., Urban P., Chiristenson J. T., Joseph D. L., Freedman R. J., Miller M. F., Ohman E. M., Reddy R. C., Stone G. W., Ferguson J. J., III. Benchmark Registry Collaborators. Intra –aortic balloon counterpulsation in US and non‐ US centres: results of the Benchmark Registry. Eur Heart J 2003; 24: 1763–1770
  • Stone G. W., Ohman E. M., Miller M. F., Joseph D. L., Christenson J. T., Cohen M., Urban P. M., Reddy R. C., Freedman R. J., Staman K. L., Ferguson J. J., III. Contemporary utilization and outcomes of intra‐aortic balloon counterpulsation in acute myocardial infarction . J Am Coll Cardiol 2003; 41: 1940–1945
  • Barron H. V., Every N. R., Parsons L. S., Angeja B., Goldberg R. J., Gore J. M., Chou T. M. The use of intra aortic balloon counterpulsation in patients with cardiologenic shock complicating acute myocardial infarction; date from the National Registry of Myocardial infarction ‐2. Am Heart J 2001; 141: 933–939
  • Gold H. K., Leinbach R. C., Saners C. A., Buckley M. J., Mundth E. D., Austen W. G. Intra‐aortic balloon pumping for ventricular septal defect or mitral regurgitation complication acute myocardial infarction. Circulation 1973; 47: 1191–1196
  • Fotopoulos G. D., Mason M. J., Walker S., Jepson N. S., Patel D. J., Mtchell A. G., Ilsley C. D., Paul V. E. Stabilisation of medically refractory ventricular arrythmias by intra‐aortic balloon counterpulsation . Heart 1999; 82: 96–100
  • Mishra Sundeep, Chu William W., Torguson Rebecca, Wolfarm Roswitha, Deible Regina, Suddath Willam O., Pichard Augusto D., Satler Lowell F., Kent Kenneth M., Waksman Ron. Role of prophylactic intra‐aortic balloon pump high‐ risk patients undergoing percutaneous coronary intervention. AM. J. Cardiol 2006; 98: 608–612
  • Briguori Carlo, Airoldi Flavio, Chieffo Alaide, Montorfano Matteo, Carlino Mauro, Sangiorgi Giuseppe Massimo, Morici Nuccia, Michev Iassen, Iakovou Ioannis, Biondi‐Zoccai Giuseppe, Colombo Antonio. Elective versus provisional intraaortic balloon pumping in unptotected left main stenting. American Heart Journal September 2006; 152: 565–72
  • Christenson J. T., Simonet F., Badel P., et al. Evaluation of pre‐operative intra‐aortic balloon pump support in high risk patients. Eur J Cardiothorac Surg 1997; 11((6))1097–1103
  • Hausmann H., Patapov E. V., Koster A., Krabatsch T., Stein J., Yater R., Kukucka M., Sodian R., Kuppe, Hetzer R. Prognosis after the implantation of an intra‐aortic balloon pump in cardiac surgery calculated with a new score. 2002 Sep 24; 106((12 Suppl 1))203–6
  • Saeed D., El‐Banayosy A., Zittermann A., Fritzsche D., Mirow N., Morshuis M., Koerfer R. A risk score to predict 30‐day mortality in patients with intra‐aortic balloon pump implantation. 2007 Apr; 55((3))163–7
  • Schreuder Jan J., Maisano Francesco, Donelli Andrea, Jansen Jos R. C., Hanlon Pat, Bovelander Jan, Alfieri Ottavio. Beat to beat effects of intraaortic balloon pump timing on left ventricular performance in patients with low efection fraction. The Ann Thorac Surg 2005; 79: 872–80
  • Erdogan Hasan Basri, Goksedef Deniz, Erentug Vedat, Polat Adil, Bozbuga Nilgun, Mansuroglu Denyan, Guler Mustafa, Akinci Esat, Yakut Cevat. In which patients should sheathless IABP be used? An analysis of vascular complications in 1211 cases. J Card Surg 2006; 21: 342–346

References

  • Guidelines on diagnosis and management of acute pulmonary embolism. Eur Heart J 2000; 21: 1301–1336
  • Piazza G., Goldhaber S. Z. Acute pulmonary embolism. Circulation 2006; 114: e28–e47, Part 1, Part 2
  • Diagnostic pathway in acute pulmonary embolism. PIOPED II. Am J Medicine 2006; 119: 1048
  • Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. MAPPET‐3 Trial. NEJM 2002; 347: 1143–50
  • Comparative efficacy of two hours regimen of streptokinase versus alteplase in acute massive pulmonary embolism. JACC 1998; 31: 1057
  • Becattini C., Vedovati M. C., Agnelli G. Prognosis value of troponins in acute pulmonary embolism. A meta‐analysis. Circulation 2007, July 2; 116, (Epub ahead of print)
  • Sukhija R., Aronow W. S., Lee J., et al. Association of right ventricular dysfunction with in‐hospital mortality in patients with acute pulmonary embolism. Am J Cardiol 2005; 95: 695–6
  • Barrit D. W., Lond M. D., Jordan S. C. Anticoagulant drugs in the treatment of pulmonary embolism: a controlled trial. Lancet 1960; 1: 1309–12
  • Rahimtoola A., Bergin J. D. Acute PE: An update on diagnosis and management. Curr Probl Cardiol 2005 Feb; 30((2))61–114

References

  • Nolan J. P., Baskett P. European Resuscitation Council guidelines for resuscitation 2005. Resuscitation 2005 Dec; 67(Suppl 1)S1–189
  • Rea T. D., Helbock M., Perry S., Garcia M., Cloyd D., Becker L., et al. Increasing use of cardiopulmonary resuscitation during out‐of‐hospital ventricular fibrillation arrest: survival implications of guideline changes. Circulation 2006 Dec 19; 114((25))2760–5
  • Hallstrom A., Rea T. D., Sayre M. R., Christenson J., Anton A. R., Mosesso V. N, Jr., et al. Manual chest compression vs use of an automated chest compression device during resuscitation following out‐of‐hospital cardiac arrest: a randomized trial. Jama 2006 Jun 14; 295((22))2620–8
  • Axelsson C., Nestin J., Svensson L., Axelsson A. B., Herlitz J. Clinical consequences of the introduction of mechanical chest compression in the EMS system for treatment of out‐of‐hospital cardiac arrest‐a pilot study. Resuscitation 2006 Oct; 71((1))47–55
  • Englund E. Tissue injuries after CPR. Resuscitation 2006; 69: 71–2
  • KftS‐Ksg Nagao. Cardiopulmonary resuscitation by bystanders with chest compression only (SOS‐KANTO): an observational study. Lancet 2007 Mar 17; 369((9565))920–6
  • Koster R. W., Deakin C. D., Bottiger B. W., Zideman D. A. Chest‐compression‐only or full cardiopulmonary resuscitation?. Lancet 2007 Jun 9; 369((9577))1924, author reply 5

References

  • Fuster V., Rydén L. E., Cannom D. S., et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 2006; 48: e149–e246
  • Fuster V., Rydén L. E., Asinger R. W., et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): developed in Collaboration With the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol 2001; 38: 1231–1266

References

  • Ferrari, et al. Il rimodellamento cardiaco. Monografie di Cardiologia, SIC 2003
  • Calderone A., Takahashi N., Izzo N. J., et al. Pressure and volume‐induced left vetricular hypertrophics are associated with distinct myocyte phenotypes and differential induction of peptide growth factor mRNAs. Circulation 1995; 92: 2385–2390
  • Kerr J. F., Wyllie A. H., Currie A. R. Apoptosis, a basic biological phenomenon with a wide‐ranging implications in tissue kinetics. BR J Cancer 1972; 26: 239–257
  • Chevalier B., Callens F., Cahrlemagne D., et al. Signal and adaptational changes in gene expression during cardiac overload. J Mol Cell Cardiol 1989; 21: 71–77
  • Simpson P. C., Karns L. R., Long C. S. An approach to the molecular regulation of cardiac myocyte hypertrophy. Molecular biology of the cardiovascular system, S Chien. Lea & Febiger, Philadelphia 1990; 53–81
  • Zolk O., Ng L. L., O'Brian R. J., et al. Augmented expression of cardiotrophin‐1 in failing human hearts is accompanied by diminished glycoprotein 130 receptor protein abundance. Circulation 2002; 160: 1442–1446
  • Elken Hg., Øle E., Damas J. K., et al. Myocardial gene expression of leukaemia inhibitory factor, interleukin‐6 and glycoprotein 130 in end‐stage human heart failure. Eur J Clin Invest 2001; 31: 389–397
  • Heinrich P. C., Behrmann I., Müller‐Nuwen G., et al. Interlukin‐6‐type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 1998; 334: 297–314

References

  • Sutton M. G., Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation 2000; 101: 2981–8
  • Savoye C., Equine O., Tricot O., Nugue O., Segrestin B., Sautiere K., Elkohen M., Pretorian E. M., Taghipour K., Philias A., Aumegeat V., Decoulx E., Ennezat P. V., Bauters C. Left ventricular remodeling after anterior wall acute myocardial infarction in modern clinical practice (from the REmodelage VEntriculaire [REVE] study group). Am J Cardiol 2006; 98: 1144–9
  • Jugdutt B. I. Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough?. Circulation 2003; 108: 1395–403
  • Leor J., Landa N., Cohen S. Renovation of the injured heart with myocardial tissue engineering. Expert Rev Cardiovasc Ther 2006; 4: 239–52
  • Christman K. L., Lee R. J. Biomaterials for the treatment of myocardial infarction. J Am Coll Cardiol 2006; 48: 907–13
  • Davis M. E., Motion J. P., Narmoneva D. A., Takahashi T., Hakuno D., Kamm R. D., Zhang S., Lee R. T. Injectable self‐assembling peptide nanofibers create intramyocardial microenvironments for endothelial cells. Circulation 2005; 111: 442–50
  • Davis M. E., Hsieh P. C., Grodzinsky A. J., Lee R. T. Custom design of the cardiac microenvironment with biomaterials. Circ Res 2005; 97: 8–15
  • Wall S. T., Walker J. C., Healy K. E., Ratcliffe M. B., Guccione J. M. Theoretical impact of the injection of material into the myocardium: a finite element model simulation. Circulation 2006; 114: 2627–35
  • Dai W., Wold L. E., Dow J. S., Kloner R. A. Thickening of the infarcted wall by collagen injection improves left ventricular function in rats: a novel approach to preserve cardiac function after myocardial infarction. J Am Coll Cardiol 2005; 46: 714–9
  • Kofidis T., Lebl D. R., Martinez E. C., Hoyt G., Tanaka M., Robbins R. C. Novel injectable bioartificial tissue facilitates targeted, less invasive, large‐scale tissue restoration on the beating heart after myocardial injury. Circulation 2005; 112: I173–7
  • Migrino R. Q., Young J. B., Ellis S. G., White H. D., Lundergan C. F., Miller D. P., Granger C. B., Ross A. M., Califf R. M., Topol E. J. End‐systolic volume index at 90 to 180 minutes into reperfusion therapy for acute myocardial infarction is a strong predictor of early and late mortality. The Global Utilization of Streptokinase and t‐PA for Occluded Coronary Arteries (GUSTO)‐I Angiographic Investigators. Circulation 1997; 96: 116–21
  • Gaudette G. R., Cohen I. S. Cardiac regeneration: materials can improve the passive properties of myocardium, but cell therapy must do more. Circulation 2006; 114: 2575–7
  • Christman K. L., Vardanian A. J., Fang Q., Sievers R. E., Fok H. H., Lee R. J. Injectable fibrin scaffold improves cell transplant survival, reduces infarct expansion, and induces neovasculature formation in ischemic myocardium. J Am Coll Cardiol 2004; 44: 654–660
  • Christman K. L., Fok H. H., Sievers R. E., Fang Q., Lee R. J. Fibrin glue alone and skeletal myoblasts in a fibrin scaffold preserve cardiac function after myocardial infarction. Tissue Eng 2004; 10: 403–9
  • Hao X., Silva E. A., Mansson‐Broberg A., Grinnemo K. H., Siddiqui A. J., Dellgren G., Wardell E., Brodin L. A., Mooney D. J., Sylven C. Angiogenic effects of sequential release of VEGF‐A(165) and PDGF‐BB with alginate hydrogels after myocardial infarction. Cardiovasc Res 2007
  • Leor J., Amsalem Y., Cohen S. Cells, scaffolds, and molecules for myocardial tissue engineering. Pharmacol Ther 2005; 105: 151–63
  • Hsieh P. C., Davis M. E., Gannon J., Macgillivray C., Lee R. T. Controlled delivery of PDGF‐BB for myocardial protection using injectable self‐assembling peptide nanofibers. J Clin Invest 2006; 116: 237–248
  • Davis M. E., Hsieh P. C., Takahashi T., Song Q., Zhang S., Kamm R. D., Grodzinsky A. J., Anversa P., Lee R. T. Local myocardial insulin‐like growth factor 1 (IGF‐1) delivery with biotinylated peptide nanofibers improves cell therapy for myocardial infarction. Proc Natl Acad Sci U S A 2006; 103: 8155–60
  • Christman K. L., Fang Q., Yee M. S., Johnson K. R., Sievers R. E., Lee R. J. Enhanced neovasculature formation in ischemic myocardium following delivery of pleiotrophin plasmid in a biopolymer. Biomaterials 2005; 26: 1139–44
  • Leor J., Aboulafia‐Etzion S., Dar A., Shapiro L., Barbash I. M., Battler A., Granot Y., Cohen S. Bioengineered cardiac grafts: A new approach to repair the infarcted myocardium?. Circulation 2000; 102: III56–61
  • Kofidis T., de Bruin J. L., Hoyt G., Lebl D. R., Tanaka M., Yamane T., Chang C‐P., Robbins R. C. Injectable bioartificial myocardial tissue for large‐scale intramural cell transfer and functional recovery of injured heart muscle. J Thorac Cardiovasc Surg 2004; 128: 571–578
  • Lee K. Y., Mooney D. J. Hydrogels for tissue engineering. Chem Rev 2001; 101: 1869–79
  • Landa N., Feinberg M. S., Holbova H., Miller L., Cohen S., Leor J. Novel injectable alginate biomaterial attenuates progressive infarct expansion and preserves left ventricular systolic and diastolic function late after mycardial nifarction (abstract). Eur Heart J 2005, (Suppl)
  • Leor J., Guetta V., Horvath I., Manzur F., Simor T., Petrasi Z., Freeman I., Feinberg M. S., Tuvia S., Cohen S. Transcoronary injection of a novel alginate‐based biomaterial improve cardiac remodeling and function early after myocardial infarction in pig (abstract). Eur Heart J 2007, (Suppl)
  • Leor J., Miller L., Feinberg M. S., Shachar S., Landa N., Holbova R., Choen S. A novel injectable alginate scaffold promotes angiogenesis and preserves left ventricular geometry and function after extensive myocardial infarction in rat (abstract). Circulation 2004, (Suppl)
  • Miller L., Feinberg M. S., Shachar S., Landa N., Holbova R., Choen S., Leor J. Injectable Tissue Engineering: A New Strategy to Reload the Extracellular Matrix and Prevent Left Ventricular Remodeling and Dysfunction (abstract). Circulation 2004, (suppl)
  • Cabrales P., Tsai A. G., Intaglietta M. Alginate plasma expander maintains perfusion and plasma viscosity during extreme hemodilution. Am J Physiol Heart Circ Physiol 2005; 288: H1708–16
  • Al‐Shamkhani A., Duncan R. Radioiodination of alginate via covalently‐bound tyrosinamide allows for monitoring of its fate in vivo. J Bioact Compat Polym 1995; 10: 4–13
  • Etzion S., Battler A., Barbash I. M., Cagnano E., Zarin P., Granot Y., Kedes L. H., Kloner R. A., Leor J. Influence of embryonic cardiomyocyte transplantation on the progression of heart failure in a rat model of extensive myocardial infarction. J Mol Cell Cardiol 2001; 33: 1321–30
  • Reffelmann T., Leor J., Muller‐Ehmsen J., Kedes L., Kloner R. A. Cardiomyocyte transplantation into the failing heart‐new therapeutic approach for heart failure?. Heart Fail Rev 2003; 8: 201–11

References

  • Beltrami A. P., Barlucchi L., Torella D., Baker M., Limana F., Chimenti S., Kasahara H., Rota M., Musso E., Urbanek K., Leri A., Kajstura J., Nadal‐Ginard B. Anversa P: Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 2003; 114: 763–776
  • Itzhaki A., Leor J., Mishali D., Sheich Yosef B., Raanani E. Barbash IM: The hearts of patients with heart disease retain progenitor cells with regenerative capacity. J Mol Cell Cardiol 2007; 42((6))S94, Suppl 1
  • Laugwitz K. L., Moretti A., Lam J., Gruber P., Chen Y., Woodard S., Lin L. Z., Cai C. L., Lu M. M., Reth M., Platoshyn O., Yuan J. X., Evans S. Chien KR: Postnatal isl1+ cardioblasts enter fully differentiated cardiomyocyte lineages. Nature 2005; 433: 647–653
  • Jackson K. A., Majka S. M., Wang H., Pocius J., Hartley C. J., Majesky M. W., Entman M. L., Michael L. H., Hirschi K. K. Goodell MA: Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. J Clin Invest 2001; 107: 1395–1402

References

  • Assmus B., Honold J., Schachinger V., Britten M. B., Fischer‐Rasokat U., Lehmann R., Teupe C., Pistorius K., Martin H., Abolmaali N. D., Tonn T., Dimmeler S., Zeiher A. M. Transcoronary transplantation of progenitor cells after myocardial infarction. N Engl J Med 2006; 355: 1222–1232
  • Bartunek J., Vanderheyden M., Vandekerckhove B., Mansour S., De Bruyne D., De Bondt P., Van Houter I., Lootens N., Heyndrickx G., Wijns W. Intracoronary injection of CD133‐positive enriched bone marrow progenitor cells promotes cardiac recovery after recent myocardial infarction: feasibility and safety. Circulation 2005; 112: 178–183
  • Chen S. L., Fang W. W., Ye F. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol 2004; 94: 92–95
  • Fuchs S., Kornowski R., Weisz G., Satler L. F., Smits P. C., Okubagzi P., Baffour R., Aggarwal A., Weissman N. J., Cerqueira M., Waksman R., Serrruys P., Battler A., Moses J. W., Leon M. B., Epstein S. E. Safety and feasibility of transendocardial autologous bone marrow cell transplantation in patients with advanced heart disease. Am J Cardiol 2006; 97((6))823–9
  • Perin E. C., Dohmann H. F., Borojevic R., et al. Improved exercise capacity and ischemia 6 and 12 months after transendocardial injection of autologous bone marrow mononuclear cells for ischemic cardiomyopathy. Circulation 2004; 110((11 Suppl 1))II213–218
  • Menasché P. Skeletal myoblasts as a therapeutic agent. Prog Cardiovasc Dis 2007; 50: 7–17
  • Engelmann M. G., Theiss H. D., Hennig‐Theiss C., Huber A., Wintersperger B. J., Werle‐Ruedinger A. E., Schoenberg S. O., Steinbeck G., Franz W. M. Autologous bone marrow stem cell mobilization induced by granulocyte colony‐stimulating factor after subacute ST‐segment elevation myocardial infarction undergoing late revascularization: final results from the G‐CSF‐STEMI (Granulocyte Colony‐Stimulating Factor ST‐Segment Elevation Myocardial Infarction) trial. J Am Coll Cardiol 2006; 48: 1712–21
  • Abdel‐Latif A., Bolli R., Tleyjeh I. M., Montori V. M., Perin E. C., Hornung C. A., Zuba‐Surma E. K., Al‐Mallah M., Dawn B. Adult bone marrow‐derived cells for cardiac repair: a systematic review and meta‐analysis. Arch Intern Med 2007; 167: 989–97

References

  • Pfeffer M. A., Swedberg K., Granger C. B., et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failurethe CHARM‐Overall programme. Lancet 2003; 362: 759–766
  • Klein L., O'Connor C. M., Leimberger J. D., Gattis‐Stough W., Pina I. L., Felker G. M., Adams K. F Jr., Califf R. M., Gheorghiade M., OPTIME‐CHF Investigators. Lower serum sodium is associated with increased short‐term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME‐CHF) study. Circulation 2005 May 17; 111((19))2454–60
  • Publication Committee for VMAC Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002; 287: 1531–1540
  • Mebazaa A., Nieminen M. S., Packer M., Cohen‐Solal A., Kleber F. X., Pocock S. J., Thakkar R., Padley R. J., Poder P., Kivikko M., SURVIVE Investigators. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 2007 May 2; 297((17))1883–91
  • Gheorghiade M., Gattis W. A., O'Connor C. M., et al. Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial (ACTIV). JAMA 2004; 291: 1963–1971
  • Gheorghiade M., Orlandi C., Burnett J. C., et al. Rationale and design of the multicenter, randomized, double‐blind, placebo‐controlled study to evaluate the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan (EVEREST). J Card Fail 2005; 11: 260–269
  • Konstam M. A., Gheorghiade M., Burnett J. C., Jr., et al. for the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA 2007; 297: 1319–1331
  • Gheorghiade M., Konstam M. A., Burnett J. C., Jr., et al. for the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Short‐term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials. JAMA 2007; 297: 1332–1343
  • Yatsu T., Tomura Y., Tahara A., et al. Pharmacological profile of YM087, a novel nonpeptide dual vasopressin V1A and V2 receptor antagonist, in dogs. Eur J Pharmacol 1997; 321: 225–230
  • Tahara A., Tomura Y., Wada K., et al. Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin‐induced protein synthesis in neonatal rat cardiomyocyte. Cardiovasc Res 1998; 38: 198–205

References

  • Parissis J. T., Farmakis D., Nieminen M. Classical inotropes and new cardiac enhancers. Heart Fail Rev 2007; 12: 149–56
  • Shin D. D., Brandimarte F., De Luca L., Sabbah H. N., Fonarow G. C., Filippatos G., Komajda M., Gheorghiade M. Review of current and investigational pharmacologic agents for acute heart failure syndromes. Am J Cardiol 2007; 99((2A))4A–23A
  • Parissis J., Filippatos G., Farmakis D., Adamopoulos S., Paraskevaidis I., Kremastinos D. Levosimendan for the treatment of acute heart failure syndromes. Exp Opin Pharmacother 2005; 6: 2741–2751
  • Adamopoulos S., Parissis J., Iliodromitis E., et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. Am J Cardiol 2006; 98: 102–106
  • Moiseyev V. S., Poder P., Andrejevs N., et al. RUSSLAN Study Investigators. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo‐controlled, double‐blind study (RUSSLAN). Eur Heart J 2002; 23: 1422–1432
  • Follath F., Cleland J. G., Just H., et al. Steering Committee and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low‐output heart failure (the LIDO study): a randomised double‐blind trial. Lancet 2002; 360: 196–202
  • De Luca L., Colucci W. S., Nieminen M. S., Massie B. M., Gheorghiade M. Evidence‐based use of levosimendan in different clinical settings. Eur Heart J 2006; 27: 1908–1920
  • Mebazaa A., Nieminen M. S., Packer M., Cohen‐Solal A., Kleber F. X., Pocock S. J., Thakkar R., Padley R. J., Poder P., Kivikko M., SURVIVE Investigators. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 2007; 297: 1883–91
  • Nieminen M. S., Bohm M., Cowie M. R., et al. ESC Committee for Practice Guideline. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26: 384–416
  • Parissis J. T., Adamopoulos S., Farmakis D., Filippatos G., Paraskevaidis I., Panou F., Iliodromitis E., Kremastinos D. T. Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure. Heart 2006; 92: 1768–72

References

  • Amsterdam E. A., Kirk J. D., editors, Chest Pain Units, Cardiology Clinics, volume 23: number 4, November
  • Amsterdam, et al. Exercise Testing in the Emergency Department, American Heart Association Scientific Statement, in preparation

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.